Significant shortcomings in clinical thrombolysis efficiencies and arterial recanalization rates still exist to date necessitating the development of additional thrombolysis-enhancing technologies. For example, to improve tPA-induced systemic clot lysis several supplementary treatment methods have been proposed, among them ultrasound-enhanced tissue plasminogen activator (tPA) thrombolysis whic...

BACKGROUND AND PURPOSE Thrombolytic therapy with tissue plasminogen activator (tPA) in ischemic stroke is limited by increased risks of cerebral hemorrhage and brain injury. In part, these phenomena may be related to neurovascular proteolysis mediated by matrix metalloproteinases (MMPs). Here, we used a combination of pharmacological and genetic approaches to show that tPA promotes MMP-9 levels...

Abstract 3D printing in the textile and fashion industry is a new emerging technology. Applications of for designing clothes other wearable accessories require tribological biological understanding plastics against complex human skin to mitigate skin-friction related ailments such as calluses blisters. This study provides insight search an optimal printable material that has minimal friction sk...

Risk of hemorrhagic transformation, incomplete reperfusion, neurotoxicity, and a short treatment time window comprises major challenges for tissue plasminogen activator (tPA) thrombolytic stroke therapy. Improving tPA therapy has become one of the highest priorities in the stroke field. This mini review article focuses on our recent efforts aimed at evaluating a novel combination approach of lo...

We report on two-photon absorption ~TPA! photocurrent in semiconductor microcavities. We experimentally show a substantial increase in the TPA photocurrent generated, at resonance, in a GaAlAs/GaAs microcavity designed for TPA operation at ;890 nm. An enhancement factor of ;12 000 of the photocurrent is obtained via the microcavity effect, which could have an important impact on the use of TPA ...

An impaired fibrinolytic function due to elevated plasma levels of plasminogen activator inhibitor (PAI)-1 activity or tissue plasminogen activator (tPA) antigen is correlated with the development of myocardial infarction (MI) in patients with manifest coronary heart disease. Recently, methods for determining the specific tPA/inhibitor complexes constituting tPA antigen in plasma have become av...

OBJECTIVE Tissue plasminogen activator (tPA) is approved for treatment of acute ischemic stroke, but it increases the risk of cerebral hemorrhage. Accumulating evidence suggests that von Willebrand factor (VWF) plays a pivotal role in thrombus formation and microcirculatory disturbances after ischemic stroke. By cleaving VWF, ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin t...

Human promyelocytic leukemia cells (HL-60) undergo differ entiation when treated with the tumor promoter, 12-O-tetradecanoylphorbol-13-acetate (TPA). As the primary target for TPA action is membranes, studies were undertaken to determine whether phorbol ester exposure would influence fatty acid metabolism in these cells. In cells incubated with labeled fatty acids for 1 hr, the percentage of di...

BACKGROUND Although recombinant tissue plasminogen activator (tPA) improves outcomes from ischemic stroke, prior studies have found low rates of administration. Recent guidelines and regulatory agencies have advocated for increased tPA administration in appropriate patients, but it is unclear how many patients actually receive tPA. OBJECTIVE To determine whether national rates of tPA use for ...

Human promyelocytic leukemia cells (HL-60) undergo differentiation when treated with the tumor promoter, 12-O-tetradecanoylphorbol-13-acetate (TPA). As the primary target for TPA action is membranes, studies were undertaken to determine whether phorbol ester exposure would influence fatty acid metabolism in these cells. In cells incubated with labeled fatty acids for 1 hr, the percentage of dis...